Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
141 USD | +1.86% | -1.52% | +11.96% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.96% | 7.91B | C+ | ||
-1.17% | 102B | B+ | ||
+2.87% | 96.09B | B+ | ||
+2.13% | 22.28B | B | ||
-14.77% | 21.4B | B+ | ||
-8.79% | 18.14B | A- | ||
-39.98% | 17.02B | A- | ||
-13.21% | 16.09B | B | ||
+8.55% | 13.83B | C+ | ||
+35.75% | 11.97B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASND Stock
- Ratings Ascendis Pharma A/S